Resources
About Us
Home Report
Store
Europe Molecular Diagnostics Market
Europe Molecular Diagnostics Market by Product (Reagents & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab) - Forecast to 2030
Report ID:MRHC - 1041027 Pages: 180 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Europe Molecular Diagnostics Market is projected to reach $13.25 billion by 2030, at a CAGR of 4% from 2024 to 2030. Molecular diagnostics is a branch of medical and clinical laboratory science that involves the detection, identification, and measurement of specific genetic or molecular markers within a person's biological samples (e.g., blood, tissue, or other bodily fluids) to diagnose and monitor diseases, predict disease risk, and guide treatment decisions. It is a rapidly evolving field that has revolutionized the way various diseases are diagnosed and managed.
The growth of this market is driven by factors such as technological advancements in molecular diagnostics, the increasing use of PoC diagnostic tests, an increase in funding for the R&D of diagnostic products, the rising geriatric population, and the increasing prevalence of target diseases. However, unfavorable regulatory framework and cost of molecular diagnostic tests hamper the growth of this market to a notable extent. Additionally, developments in companion diagnostics are expected to offer significant growth opportunities for the players operating in the molecular diagnostics market. However, the dearth of skilled professionals is a challenging factor for the market.
Technological Advancements in Molecular Diagnostics
The healthcare landscape is constantly changing due to innovations in medical technologies. In recent years, companies have been focused on developing advanced diagnostic kits that can yield faster results than traditional kits. These advanced kits allow healthcare providers and caregivers to make crucial medical decisions promptly. For instance, companies have been developing ultra-fast PCR kits to minimize the time required to generate test results. For instance, in February 2021, Eurofins Technologies (Luxembourg) launched the GSD Nova Prime SARS-CoV-2 Direct RT-PCR kit for the qualitative detection of SARS-CoV-2 from human nasopharyngeal swabs. The GSD Nova Prime SARS-CoV-2 Direct RT-PCR kit shortens the complete turnaround time of the test, providing results in approximately one hour without compromising accuracy, allowing for a higher processing capacity.
Integrating digital technologies in clinical and ambulatory settings helps improve doctors’ and physicians’ ability to reach an initial diagnosis. Also, the digitalization of diagnostic services helps document and analyze patient data and test results, which minimizes human error and makes treatment and care pathways more consistent. Hence, an increasing number of healthcare providers are adopting digitally compatible diagnostic systems and devices to store patient data and view patients’ medical histories instantly. There are advanced digitalized molecular diagnostics products; for instance, in August 2022, F. Hoffmann-La Roche (Switzerland) launched its digital PCR system, Digital LightCycler System. The system accurately quantifies trace amounts of specific DNA and RNA targets that are not typically detected by the conventional PCR method. Hence, technological advancements drive the Europe Molecular Diagnostic Market.
Click here to: Get Free Sample Pages of this Report
Increasing Focus on Companion Diagnostics Creates an Opportunity for the Europe Molecular Diagnostics Market
Companion molecular diagnostics measure the levels of proteins, genes, or specific mutations to reveal specific and effective therapies for an individual’s condition. Companion diagnostics (CDx) is a form of personalized, stratified, and precision medicine that individualizes a patient’s treatment. CDx has expanded from oncology drugs to multiple therapeutic areas, and the number of combinations has grown significantly over the years. Also, personalized medicine for infectious diseases helps to orient the molecular management of infections. Molecular microbiology offers technologies that can detect and identify microorganisms rapidly. Determining the pharmacogenetic profiles of patients suffering from infectious diseases provides an additional assessment of the drug metabolizer phenotype and/or of the risk of potential adverse drug interactions. Personalized medicine is thus expected to help develop new therapies and new methods for disease detection.
European companies in this market are collaborating for the development and commercialization of CDx due to the growth potential of companion diagnostics. This will help the companies expand their product portfolios and strengthen their presence across regions. For instance, in April 2022, AstraZeneca plc (U.K.) and Amoy Diagnostics Co., Ltd. (China) signed a collaboration agreement for multiple companion diagnostics programs in China, Japan, and the European Union. Also, in September 2021, Merck KGaA (Germany) and Illumina, Inc. (U.S.) partnered to develop and commercialize companion diagnostic tests to identify genetic mutations in patients with HRD-positive tumors who are eligible for the PARP inhibitor targeted treatment.
Key Findings of the Europe Molecular Diagnostics Study:
In 2024, the Kits & Reagents Segment is Expected to Dominate the Europe Molecular Diagnostics Market
Among the products & services included in the report, in 2024, the reagents & kits segment is expected to account for the largest share of the Europe molecular diagnostics market. Factors such as frequent and repetitive use of molecular diagnostic reagents & kits, availability of disease-specific kits for the early diagnosis of chronic and infectious diseases, and technological advancements in molecular diagnostics contribute to the segment’s largest share.
In 2024, the Laboratory Tests Segment is Expected to Dominate the Europe Molecular Diagnostics Market
Among the test types included in the report, in 2024, the laboratory tests segment is expected to account for the largest share of the Europe molecular diagnostics market. Lab testing is the traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing. The laboratory technicians conduct the processing and testing and create a report for the clinician. The laboratory testing approach for molecular diagnostics has many advantages over other approaches. It has higher accuracy and reliability when compared to point-of-care testing, owing to which the adoption is more compared to PoC tests.
In 2024, the Polymerase Chain Reaction (PCR) Segment is Expected to Dominate the Europe Molecular Diagnostics Market
Among the technologies included in the report, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the Europe molecular diagnostics market. PCR allows rapid amplification of a specific segment of DNA. This technology is sensitive and thus helps in the diagnosis of diseases. It is effective for low-number targets and less expensive than other technologies, such as sequencing. Hence, the huge demand for PCR devices further contributes to the segment’s largest share.
In 2024, the Infectious Diseases Segment is Expected to Dominate the Europe Molecular Diagnostics Market
Among the applications included in the report, in 2024, the infectious diseases segment is expected to account for the largest share of the Europe molecular diagnostics market. The large market share of this segment is attributed to the rising incidence rates of infectious diseases and the increase in initiatives by government organizations toward their prevention by early diagnosis. In the U.K., the number of people diagnosed with sexually transmitted infections (STIs) reached 490.1 thousand in 2020 from 468.3 thousand in 2019. Thus, the growing burden of infectious diseases drives the demand for molecular diagnostics for infectious diseases.
In 2024, the Hospitals & Clinics Segment is Expected to Dominate the Europe Molecular Diagnostics Market
Among the end users included in the report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the Europe molecular diagnostics market. The high number of hospitals and clinics, the high prevalence of healthcare-associated infections (HAIs), and the increasing healthcare expenditure worldwide are driving the demand for molecular diagnostics products in the region. In Europe, several factors driving the growth in the genomic sector increase the adoption of molecular diagnostic products. For instance, the establishment of national programs or pan-European programs, such as the “1+ Million Genomes” initiative, which involves 23 countries across Europe and aims to improve the uptake of genomics by healthcare systems and in personalized healthcare.
Germany: Fastest-growing Country-level Market
Based on geography, Germany is slated to record the highest growth rate during the forecast period. The market growth in Germany is attributed to the well-established healthcare system, the rise in healthcare spending, the rising incidence of chronic diseases, the aging population, efforts by the German Government to further improve the quality of healthcare, research for the development of new technologies, and a high number of patients suffering from hospital-acquired infections. According to GLOBOCAN, in 2020, 628,519 new cancer cases and 252,065 cancer deaths were reported in Germany. The cancer incidence rate is estimated to increase to 749,559 by 2040. Additionally, according to the Robert Koch Institute (Germany), an estimated 400,000–600,000 patients get hospital-acquired infections every year, of which 10,000–15,000 succumb to these infections. Thus, the high burden of chronic and infectious diseases is driving the demand for molecular diagnostics in Germany.
Key Players
The key players profiled in this market study are F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Illumina, Inc. (U.S.).
Scope of the Report:
Europe Molecular Diagnostics Market Assessment, by Product & Service
- Kits & Reagents
- Instruments/Systems
- Software & Services
Europe Molecular Diagnostics Market Assessment, by Test Type
- Laboratory Tests
- PoC Tests
Europe Molecular Diagnostics Market Assessment, by Technology
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization (ISH)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Microarrays
- Mass Spectrometry
- Sequencing
- Other Technologies
(Note: Other Technologies include electrophoresis, southern blotting, northern blotting, and ligase chain reaction (LCR))
Europe Molecular Diagnostics Market Assessment, by Application
- Infectious Diseases
- COVID-19
- Hepatitis
- HIV
- Healthcare-associated Infections (HAIs)
- Chlamydia trachomatis/ Neisseria gonorrhoeae (CT/NG)
- Human papillomavirus (HPV)
- Tuberculosis
- Influenza
- Other Infectious Diseases
(Note: Other infectious diseases include meningococcal disease; norovirus (stomach flu); tropical diseases; hand, foot, and mouth disease (HFMD); and pertussis)
- Oncology
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Lymphoma
- Leukemia
- Cervical Cancer
- Other Cancer Types
(Note: Other cancer types include bladder cancer, melanoma, kidney cancer, stomach cancer, ovarian cancer, thyroid cancer, and chest cancer)
- Genetic Testing
- Neurological Diseases
- Cardiovascular Diseases
- Other Applications
(Note: Other applications include pharmacogenomics, forensic testing, environmental studies, educational study purposes, human & microorganism genomic research studies, and food & beverages testing.)
Europe Molecular Diagnostics Market Assessment, by End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Other End Users
(Note: Other end users include blood banks, ambulatory care centers, nursing homes, home care facilities, self-testing, the food & beverage industry, and forensic and environmental testing laboratories.)
Europe Molecular Diagnostics Market Assessment, by Geography
- Germany
- France
- U.K.
- Switzerland
- Ireland
- Belgium
- Italy
- Spain
- Rest of Europe (RoE)
Key questions answered in the report:
The Europe molecular diagnostics market study covers the market sizes & forecasts for various molecular diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the Europe molecular diagnostics market at the regional and country levels.
The Europe molecular diagnostics market is projected to reach $13.25 billion by 2030, at a CAGR of 4% during the forecast period.
Among the products & services included in the report, in 2024, the kits & reagents segment is expected to account for the largest share of the Europe molecular diagnostics market.
Among the end user included in the report, the hospitals & clinics segment is expected to grow with the highest CAGR due to the increasing patient inflow, expansion of diagnostic laboratories, and the installation of advanced molecular diagnostics products in laboratories.
The growth of this market is driven by factors such as technological advancements in molecular diagnostics, increasing use of PoC diagnostic tests, an increase in focus and funding for R&D of diagnostic products, and rising geriatric population and increasing prevalence of target diseases. In addition, companion diagnostics offering new growth potential is expected to provide significant opportunities for the growth of this market.
The key players operating in the Europe Molecular Diagnostics Market are F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Illumina, Inc. (U.S.).
Germany is projected to offer significant growth opportunities for vendors operating in this market due to the continuous improvement in the healthcare infrastructure and growing government investment in this sector.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Technological Advancements in Molecular Diagnostics
4.2.1.2. Innovations in PoC Tests
4.2.1.3. Increase in Focus and Funding for R&D of Diagnostic Products
4.2.1.4. Rising Geriatric Population
4.2.1.5. Rising Prevalence of Communicable and Non-communicable Diseases
4.2.2. Restraints
4.2.2.1. Unfavorable Regulatory Framework
4.2.2.2. High Cost of Molecular Diagnostic Tests
4.2.3. Opportunities
4.2.3.1. Companion Diagnostics to Offer New Growth Potential
4.2.4. Challenges
4.2.4.1. Lack of Skilled Professionals
4.3. Technology Trends
4.4. Regulatory Analysis
4.5. Pricing Analysis
5. Europe Molecular Diagnostics Market Assessment, by Product & Service
5.1. Overview
5.2. Reagents & Kits
5.3. Instruments/Systems
5.4. Software & Services
6. Europe Molecular Diagnostics Market Assessment, by Test Type
6.1. Overview
6.2. Lab Tests
6.3. PoC Tests
7. Europe Molecular Diagnostics Market Assessment, by Technology
7.1. Overview
7.2. Polymerase Chain Reaction (PCR)
7.3. In Situ Hybridization (ISH)
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Chips and Microarray
7.6. Mass Spectrometry
7.7. Sequencing
7.8. Transcription Mediated Amplification (TMA)
7.9. Other Technologies
8. Europe Molecular Diagnostics Market Assessment, by Application
8.1. Overview
8.2. Infectious Diseases
8.2.1. Hepatitis
8.2.2. HIV
8.2.3. Healthcare-associated Infections (HAIs)
8.2.4. Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
8.2.5. Human papillomavirus (HPV)
8.2.6. Tuberculosis
8.2.7. Influenza
8.2.8. COVID-19
8.2.9. Other Infectious Diseases
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Lung Cancer
8.3.4. Prostate Cancer
8.3.5. Lymphoma Cancer
8.3.6. Leukemia Cancer
8.3.7. Cervical Cancer
8.3.8. Other Cancer Types
8.4. Genetic Testing
8.5. Neurological Diseases
8.6. Cardiovascular Diseases
8.7. Other Applications
9. Europe Molecular Diagnostics Market Assessment, by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Other End Users
10. Europe Molecular Diagnostics Market Assessment, by Geography
10.1. Overview
10.2. Germany
10.3. France
10.4. U.K.
10.5. Switzerland
10.6. Ireland
10.7. Belgium
10.8. Italy
10.9. Spain
10.10. Rest of Europe (RoE)
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis, by the Key Player/Key Market Ranking, 2022
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Development)
12.1. F. Hoffmann-La Roche Ltd.
12.2. Hologic, Inc.
12.3. QIAGEN N.V.
12.4. Danaher Corporation
12.5. bioMérieux S.A.
12.6. Becton, Dickinson and Company (BD)
12.7. Siemens Healthineers AG
12.8. DiaSorin S.p.A.
12.9. Abbott Laboratories
12.10. Thermo Fisher Scientific Inc.
12.11. Agilent Technologies, Inc.
12.12. Illumina, Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Europe Molecular Diagnostics Market, by Product & Service, 2021–2030 (USD Million)
Table 2 Europe Molecular Diagnostics Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 3 Europe Molecular Diagnostics Instruments/Systems Market, by Country/Region, 2021–2030 (USD Million)
Table 4 Europe Molecular Diagnostics Software & Services Market, by Country/Region, 2021–2030 (USD Million)
Table 5 Europe Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 6 Europe Molecular Diagnostics Market for Laboratory Tests, by Country/Region, 2021–2030 (USD Million)
Table 7 Europe Molecular Diagnostics Market for PoC Tests, by Country/Region, 2021–2030 (USD Million)
Table 8 Europe Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 9 Europe Molecular Diagnostics Market for Polymerase Chain Reaction (PCR), by Country/Region, 2021–2030 (USD Million)
Table 10 Europe Molecular Diagnostics Market for In Situ Hybridization (ISH), by Country/Region, 2021–2030 (USD Million)
Table 11 Europe Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology (INAAT), by Country/Region, 2021–2030 (USD Million)
Table 12 Europe Molecular Diagnostics Market for Microarrays, by Country/Region, 2021–2030 (USD Million)
Table 13 Europe Molecular Diagnostics Market for Mass Spectrometry, by Country/Region, 2021–2030 (USD Million)
Table 14 Europe Molecular Diagnostics Market for Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 15 Europe Molecular Diagnostics Market for Other Technologies, by Country/Region, 2021–2030 (USD Million)
Table 16 Europe Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 17 Europe Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 18 Europe Molecular Diagnostics Market for Infectious Diseases Market, by Country/Region, 2021–2030 (USD Million)
Table 19 Europe Molecular Diagnostics Market for COVID-19 Testing, by Country/Region, 2021–2030 (USD Million)
Table 20 Europe Molecular Diagnostics Market for Hepatitis Testing, by Country/Region, 2021–2030 (USD Million)
Table 21 Europe Molecular Diagnostics Market for HIV Testing, by Country/Region, 2021–2030 (USD Million)
Table 22 Europe Molecular Diagnostics Market for CT/NG Testing, by Country/Region, 2021–2030 (USD Million)
Table 23 Europe Molecular Diagnostics Market for Human papillomavirus (HPV) Testing, by Country/Region, 2021–2030 (USD Million)
Table 24 Europe Molecular Diagnostics Market for Tuberculosis Testing, by Country/Region, 2021–2030 (USD Million)
Table 25 Europe Molecular Diagnostics Market for Influenza Testing, by Country/Region, 2021–2030 (USD Million)
Table 26 Europe Molecular Diagnostics Market for Healthcare-associated Infections (HAIs) Testing, by Country/Region, 2021–2030 (USD Million)
Table 27 Europe Molecular Diagnostics Market for Other Infectious Diseases Testing, by Country/Region, 2021–2030 (USD Million)
Table 28 Europe Molecular Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 29 Europe Molecular Diagnostics Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 30 Europe Molecular Diagnostics Market for Breast Cancer Testing, by Country/Region, 2021–2030 (USD Million)
Table 31 Europe Molecular Diagnostics Market for Colorectal Cancer Testing, by Country/Region, 2021–2030 (USD Million)
Table 32 Europe Molecular Diagnostics Market for Lung Cancer Testing, by Country/Region, 2021–2030 (USD Million)
Table 33 Europe Molecular Diagnostics Market for Prostate Cancer Testing, by Country/Region, 2021–2030 (USD Million)
Table 34 Europe Molecular Diagnostics Market for Lymphoma Testing, by Country/Region, 2021–2030 (USD Million)
Table 35 Europe Molecular Diagnostics Market for Leukemia Testing, by Country/Region, 2021–2030 (USD Million)
Table 36 Europe Molecular Diagnostics Market for Cervical Cancer Testing, by Country/Region, 2021–2030 (USD Million)
Table 37 Europe Molecular Diagnostics Market for Other Cancer Types Testing, by Country/Region, 2021–2030 (USD Million)
Table 38 Europe Molecular Diagnostics Market for Genetic Testing, by Country/Region, 2021–2030 (USD Million)
Table 39 Europe Molecular Diagnostics Market for Neurological Diseases, by Country/Region, 2021–2030 (USD Million)
Table 40 Europe Molecular Diagnostics Market for Cardiovascular Diseases, by Country/Region, 2021–2030 (USD Million)
Table 41 Europe Molecular Diagnostics Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 42 Europe Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 43 Europe Molecular Diagnostics Market for Hospitals & Clinics, by Country/Region, 2021–2030 (USD Million)
Table 44 Europe Molecular Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 45 Europe Molecular Diagnostics Market for Academic & Research Institutes, by Country/Region, 2021–2030 (USD Million)
Table 46 Europe Molecular Diagnostics Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 47 Europe Molecular Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 48 Germany: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 49 Germany: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 50 Germany: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 51 Germany: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 52 Germany: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 53 Germany: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 54 Germany: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 55 France: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 56 France: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 57 France: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 58 France: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 59 France: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 60 France: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 61 France: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 62 U.K.: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 63 U.K.: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 64 U.K.: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 65 U.K.: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 66 U.K.: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 67 U.K.: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 68 U.K.: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 69 Switzerland: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 70 Switzerland: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 71 Switzerland: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 72 Switzerland: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 73 Switzerland: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 74 Switzerland: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 75 Switzerland: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 76 Ireland: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 77 Ireland: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 78 Ireland: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 79 Ireland: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 80 Ireland: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 81 Ireland: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 82 Ireland: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 83 Belgium: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 84 Belgium: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 85 Belgium: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 86 Belgium: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 87 Belgium: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 88 Belgium: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 89 Belgium: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 90 Italy: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 91 Italy: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 92 Italy: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 93 Italy: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 94 Italy: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 95 Italy: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 96 Italy: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 97 Spain: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 98 Spain: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 99 Spain: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 100 Spain: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 101 Spain: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 102 Spain: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 103 Spain: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 104 Rest of Europe: Molecular Diagnostics Market, by Product, 2021–2030 (USD Million)
Table 105 Rest of Europe: Molecular Diagnostics Market, by Test Type, 2021–2030 (USD Million)
Table 106 Rest of Europe: Molecular Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 107 Rest of Europe: Molecular Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 108 Rest of Europe: Molecular Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 109 Rest of Europe: Molecular Diagnostics Market for Oncology, by Type, 2021–2030 (USD Million)
Table 110 Rest of Europe: Molecular Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 111 Recent Developments by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Estimation
Figure 7 Europe Molecular Diagnostics Market, by Product & Service, 2024 VS. 2030 (USD Million)
Figure 8 Europe Molecular Diagnostics Market, by Test Type, 2024 VS. 2030 (USD Million)
Figure 9 Europe Molecular Diagnostics Market, by Technology, 2024 VS. 2030 (USD Million)
Figure 10 Europe Molecular Diagnostics Market, by Application, 2024 VS. 2030 (USD Million)
Figure 11 Europe Molecular Diagnostics Market, by End User, 2024 VS. 2030 (USD Million)
Figure 12 Molecular Diagnostics Market, by Geography
Figure 13 Europe Molecular Diagnostics Market, by Product & Service, 2024 VS. 2030 (USD Million)
Figure 14 Europe Molecular Diagnostics Market, by Test Type, 2024 VS. 2030 (USD Million)
Figure 15 Europe Molecular Diagnostics Market, by Technology, 2024 VS. 2030 (USD Million)
Figure 16 Europe Molecular Diagnostics Market, by Application, 2024 VS. 2030 (USD Million)
Figure 17 Europe Molecular Diagnostics Market, by End User, 2024 VS. 2030 (USD Million)
Figure 18 Europe Molecular Diagnostics Market, 2024 VS. 2030 (USD Million)
Figure 19 Europe: Molecular Diagnostics Market Snapshot
Figure 20 Key Growth Strategies Adopted by Leading Players, 2020—2024
Figure 21 Europe Molecular Diagnostics Market: Competitive Benchmarking, by Product & Service
Figure 22 Europe Molecular Diagnostics Market: Competitive Dashboard
Figure 23 Europe Molecular Diagnostics Market: Market Share Analysis (2022)
Figure 24 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 25 Hologic, Inc.: Financial Overview (2022)
Figure 26 QIAGEN N.V.: Financial Overview (2022)
Figure 27 Danaher Corporation: Financial Overview (2022)
Figure 28 bioMérieux S.A.: Financial Overview (2022)
Figure 29 Becton, Dickinson and Company: Financial Overview (2022)
Figure 30 Siemens Healthineers AG: Financial Overview (2022)
Figure 31 DiaSorin S.p.A.: Financial Overview (2022)
Figure 32 Abbott Laboratories: Financial Overview (2022)
Figure 33 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 34 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 35 Illumina, Inc.: Financial Overview (2022)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
North America Molecular Diagnostics Market - Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: Feb-2024
